Silexion Therapeutics (Moringa Acquisition) ^{Priced, Nasdaq: SLXN}

We are a newly formed blank check company. While we may pursue a business combination target in any business or industry and across any geographical region, we intend to focus our search on technology-based businesses that are domiciled in Israel, that carry out all or a substantial portion of their activities in Israel, or that have some other significant Israeli connection. Our acquisition strategy is to identify and complete a business combination with respect to an untapped opportunity within our target Israeli high-tech industry and offer a public-ready business a facility through which to enter the public sphere, access capital markets and advance its priorities. We intend to focus on mid-size Israel-related technology companies that have a proven model of commercial success and a track record in generating and growing revenues, and, in some cases, profits. We will also seek to identify companies that are developing disruptive technology, which show very strong market potential. We believe that we are uniquely positioned to leverage our sponsor’s and its members’ successful track record growing Israeli technology companies into large, successful publicly-traded entities, and their deep network of contacts and corporate relationships around the world, and in our target region, Israel, in particular.